

# Ewa Kalinka-Warzocha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9475381/publications.pdf>

Version: 2024-02-01

76  
papers

8,487  
citations

361413

20  
h-index

155660

55  
g-index

76  
all docs

76  
docs citations

76  
times ranked

12734  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 1222.	3.7	8
2	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. <i>Targeted Oncology</i> , 2021, 16, 357-367.	3.6	13
3	Viral Infection and Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 577514.	2.8	1
4	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	1.6	55
5	First-line R-CHOP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	2.5	16
6	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119
7	Immunotherapie des Bronchialkarzinoms: Mehr als PD-L1-Marker. <i>Karger Kompass Onkologie</i> , 2020, , 5-15.	0.0	0
8	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. <i>Targeted Oncology</i> , 2020, 15, 301-315.	3.6	37
9	Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group. <i>Archives of Medical Science</i> , 2020, 16, 157-161.	0.9	1
10	The impact of cancer treatment on cognitive efficiency. <i>European Journal of Psychiatry</i> , 2020, 34, 20-26.	1.3	4
11	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
12	420...Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. , 2020, , .		5
13	Niedokrwiistość u chorych na nowotwory – zalecenia grupy ekspertów. Aktualizacja 2020 r.. <i>Oncology in Clinical Practice</i> , 2020, 16, 261-269.	0.1	0
14	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in Poland: analysis of patient series and practical guidelines for breast surgeons. <i>Archives of Medical Science</i> , 2020, , .	0.9	0
15	Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. <i>Leukemia and Lymphoma</i> , 2019, 60, 341-348.	1.3	6
16	Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study. <i>Croatian Medical Journal</i> , 2019, 60, 166-173.	0.7	5
17	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	4.1	61
18	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347

#	ARTICLE	IF	CITATIONS
19	Population morbidity in elderly lung cancer patients from Poland with specific trends in elderly women. <i>Przegląd Menopauzalny</i> , 2019, 18, 161-165.	1.3	0
20	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
21	Long-term analysis of occurrence of malignant lip, oral cavity and pharyngeal cancer in Poland. <i>Nowotwory</i> , 2019, 69, 157-162.	0.3	1
22	Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 28, 67-73.	1.4	10
23	Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. <i>Oncology Letters</i> , 2017, 13, 4433-4444.	1.8	53
24	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2017, 106, 794-800.	1.6	6
25	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.	2.4	14
26	Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. <i>Journal of Clinical Oncology</i> , 2017, 35, 4526-4526.	1.6	3
27	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 212-212.	1.6	3
28	Guidelines for the diagnosis and management of osteoporosis in Poland : Update 2017. <i>Endokrynologia Polska</i> , 2017, 68, 604-609.	1.0	30
29	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, e16537-e16537.	1.6	0
30	Cutaneous melanoma – guidelines for diagnostics and therapy in 2016. <i>Przegląd Dermatologiczny</i> , 2016, 1, 1-18.	0.1	0
31	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	2.3	12
32	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	5.0	90
33	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
34	Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients. <i>Annals of Oncology</i> , 2016, 27, 358-359.	1.2	16
35	The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. <i>Pathology and Oncology Research</i> , 2016, 22, 49-56.	1.9	10
36	MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). <i>Journal of Clinical Oncology</i> , 2016, 34, 4007-4007.	1.6	40

#	ARTICLE	IF	CITATIONS
37	Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. Journal of Clinical Oncology, 2016, 34, TPS9105-TPS9105.	1.6	6
38	Evofofosamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. Journal of Clinical Oncology, 2016, 34, 193-193.	1.6	20
39	Czerniaki skłóty " zasady postępowania diagnostyczno-terapeutycznego w 2016 roku. Nowotwory, 2016, 65, 501-516.	0.3	0
40	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. Journal of Clinical Oncology, 2016, 34, 5024-5024.	1.6	0
41	Wyniki leczenia wemurafenibem chorych na zaawansowanego czerniaka w ramach programu lekowego w Polsce. Nowotwory, 2016, 66, 118-126.	0.3	0
42	Does diabetes alter the risk of neoplasms? Real-world data analysis in Poland: incidence rates for selected neoplasms in patients with diabetes. Polish Archives of Internal Medicine, 2016, 126, 435-437.	0.4	0
43	Najważniejsze doniesienia dotyczące nowotworów w układach chłonnych z dorocznej konferencji Amerykańskiego Towarzystwa Onkologii Klinicznej w 2016 roku. Hematologia, 2016, 7, 117-127.	0.0	0
44	Leczenie chorych z chłoniakami i współistniejącym zakażeniem wirusami HCV, HBV lub HIV. Acta Haematologica Polonica, 2015, 46, 86-93.	0.3	0
45	Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma. Genes Chromosomes and Cancer, 2015, 54, 185-193.	2.8	18
46	Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study. Wspolczesna Onkologia, 2015, 3, 214-219.	1.4	6
47	Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro-Oncology, 2015, 17, 1241-9.	1.2	24
48	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine, 2015, 372, 320-330.	27.0	4,795
49	The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 61-68.	2.5	32
50	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. Journal of Translational Medicine, 2015, 13, .	4.4	12
51	Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. Medical Oncology, 2015, 32, 236.	2.5	6
52	Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer, 2015, 18, 360-367.	5.3	9
53	Postępy w diagnostyce i leczeniu chorych na chłoniaki nie-Hodgkina. Hematologia, 2015, 6, 31-43.	0.0	2
54	Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer. Postępy Higieny I Medycyny Doswiadczalnej, 2015, 69, 586-97.	0.1	8

#	ARTICLE	IF	CITATIONS
55	Immune response in breast cancer brain metastases (BM) and their microenvironment.. Journal of Clinical Oncology, 2015, 33, e22112-e22112.	1.6	0
56	Attitudes of Physicians Toward Risk Assessment and Use of Granulocyte-Colony Stimulating Factor (G-Csf) As Primary Prophylaxis (Pp) in Patients (Pts) Receiving Chemotherapy with an Intermediate Risk of Febrile Neutropenia (Fn). Annals of Oncology, 2014, 25, iv522.	1.2	0
57	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2047-2057.	2.5	28
58	Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients. Clinical Lung Cancer, 2014, 15, 455-465.	2.6	6
59	Zastosowanie wemurafenibu u chorych na uogÅ³lnionego czerniaka z obecnoÅci... mutacji w genie BRAF â€” wybrane przypadki kliniczne. Nowotwory, 2014, 64, 1-19.	0.3	0
60	Human Leukocyte Antigen-G Polymorphisms Influence Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1643-1643.	1.4	0
61	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1642-1642.	1.4	0
62	Hodgkin Lymphoma in Older Patients- a Retrospective Analysis of the Polish Lyphoma Reasearch Group. Blood, 2014, 124, 1737-1737.	1.4	3
63	CECOG expertsâ€™ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 75-82.	0.5	1
64	Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncology Reports, 2013, 30, 2385-2398.	2.6	23
65	The analysis of ALK gene rearrangement by fluorescence in situ hybridisation in non-small cel lung cancer patients. Wspolczesna Onkologia, 2013, 6, 484-492.	1.4	5
66	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Wspolczesna Onkologia, 2013, 3, 257-262.	1.4	11
67	Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe.. Journal of Clinical Oncology, 2013, 31, 128-128.	1.6	0
68	Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases.. Journal of Clinical Oncology, 2012, 30, 603-603.	1.6	2
69	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylooxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	1.4	2
70	Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers.. Blood, 2009, 114, 1702-1702.	1.4	0
71	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated lowâ€grade Bâ€cell nonâ€Hodgkin lymphoma patients. Cancer, 2008, 113, 367-375.	4.1	22
72	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 2007, 46, 500-507.	2.8	23

#	ARTICLE	IF	CITATIONS
73	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. <i>Tissue Antigens</i> , 2007, 71, 071029015950001-???.	1.0	11
74	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma. <i>Journal of Clinical Immunology</i> , 2007, 27, 339-346.	3.8	34
75	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma: Final Report after Two Epidemic Seasons.. <i>Blood</i> , 2006, 108, 4598-4598.	1.4	0
76	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. <i>Blood</i> , 2002, 100, 3037-3040.	1.4	78